|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Downregulation of costimulatory molecule CD28 is a hallmark of senescent T cells and increased CD8<sup>+</sup>CD28<sup>-</sup> senescent populations with heterogeneous roles have been observed in multiple solid and hematogenous tumors.
|
31181772 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We generated an antibody specific for phosphorylated PD-1-Y248 and examined PD-1pY248<sup>+</sup> (pPD-1) expression in human T cells. pPD-1 was upregulated by TCR/CD3 + CD28 stimulation and simultaneous PD-1 ligation. pPD-1<sup>+</sup>CD8<sup>+</sup> T cells were identified in human peripheral blood and had impaired effector function. pPD-1<sup>+</sup> T cells were also detected in tumor-draining lymph nodes of tumor bearing mice and in biopsies of patients with glioblastoma multiform.
|
31754127 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Both hu8E5-28Z and hu8E5-2I-28Z CAR T cells comprising the CD28 costimulatory domain potently suppressed tumor growth in a cancer cell line xenograft mouse model (mean [SD] tumor volume: hu8E5-28Z = 118.0 [108.6] mm3 and hu8E5-2I-28Z group = 75.5 [118.7] mm3 vs untransduced T cell group = 731.8 [206.3] mm3 at day 29 after tumor inoculation, P < .001).
|
30203099 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
According to multivariate logistic analyses, the CD8+CD28+ T-cell count predicted a 1-month tumor response to SABR (OR 0.19, 95% CI 0.04-0.90; P = 0.037) independently.
|
30971280 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, CD28 is not critical, but optimizes the formation of tumor-homing Treg and their fitness in tumor tissue.
|
29661826 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in LUAD.
|
30152019 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When injected into the pleural effusion of a patient with MPM, the Δ-CD28 CAR could be detected for up to 21 days and showed functionality.<b>Conclusions:</b> Overall, anti-FAP-Δ-CD28/CD3ζ CAR T cells revealed superior <i>in vitro</i> functionality, better tumor control in combination with PD-1 blockade in humanized mice, and persistence up to 21 days in a patient with MPM.
|
29748183 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently our group demonstrated that CD8+CD28-CD127lowCD39+ regulatory T lymphocytes, previously found highly concentrated within tumor microenvironment, circulate with elevated frequency in the peripheral blood of HIV infected patients.
|
30459765 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In vivo, a single intratumoral injection of IL13Rα2-CAR.CD28.ζ T cells significantly extended the survival of IL13Rα2-expressing GL261 and SMA560 glioma-bearing mice; long-term survivors were resistant to re-challenge with IL13Rα2-negative and IL13Rα2-positive tumors.
|
29503195 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a solid tumor model, TAC-T cells outperform CD28-based CAR-T cells with increased anti-tumor efficacy, reduced toxicity, and faster tumor infiltration.
|
30076299 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The TILs from recurrent IFS tumors expressed high levels of costimulatory molecules such as CD28, 4-1BB, and OX40, but little or no coinhibitory molecules such as PD-1 and CTLA4, Tim3, Lag3, and CD39.
|
28921877 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also evaluated HER2-CAR T cells delivered by intravenous, local intratumoral, or regional intraventricular routes of administration using <i>in vivo</i> human xenograft models of breast cancer that have metastasized to the brain.<b>Results:</b> Here, we have shown that HER2-CARs containing the 4-1BB costimulatory domain confer improved tumor targeting with reduced T-cell exhaustion phenotype and enhanced proliferative capacity compared with HER2-CARs containing the CD28 costimulatory domain.
|
29061641 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The chPD1-Dap10 T cells also had enhanced in vivo persistence and anti-tumour efficacy compared with chPD1-CD28 T cells.
|
28670716 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Interruption of CD28:ligand interactions may be an effective, targeted therapy for a subset of patients whose tumors bear the mutant CD28 receptor.
|
28711152 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An analysis of a panel of CD200R-CD28 IFP constructs revealed that the most effective costimulation was achieved in IFPs containing a dimerizing motif and a predicted tumor-T-cell distance that facilitates localization to the immunological synapse.
|
29042364 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In conclusion, CD28 may be a tumor suppressor gene and rs3116496 polymorphism of <i>CD28</i> gene showed positively correlation with the increased risk of BC.
|
29089469 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study was to evaluate the feasibility and safety of using anti-human CD70 CARs to treat cancer patients whose tumors express CD70.<b>Experimental Design:</b> Seven anti-human CD70 CARs with binding moieties from human CD27 combined with CD3-zeta and different costimulatory domains from CD28 and/or 41BB were constructed.
|
27803044 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, CARs with hinge and transmembrane regions from either CD8α or CD28 had similar abilities to eliminate established tumors in mice.
|
28807568 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor immune regulation has been demonstrated in clinical studies using antibodies targeted to the B7/CD28 family.
|
27632942 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The frequencies of effector (IFNγ+ and IL17+ T cells) and regulatory (CD4+CD25hiCD127lo and CD8+CD28-CD127loCD39+ Treg) T cell subpopulations among tumor infiltrating lymphocytes were analyzed by immunofluorescence, while the gene expression of MAGE-A1 and MAGE-A2 tumor-associated antigens was studied by RT-PCR.
|
26824503 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data argue that TCR transgenes that contain CD28, and, thereby, may provide T cell costimulation in an immune-suppressive environment, represent candidate receptors to treat patients with tumors.
|
25320284 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This tumor regression was similar to that achieved with CD28- or 4-1BB-costimulated CARs, and heightened persistence was similar to 4-1BB but greater than CD28.
|
22117050 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The relationship between the CD28 variants and clinical features, including histological grade, tumor size, lymph node metastasis, human epidermal growth factor receptor 2 (C-erbB2), estrogen receptor (ER), progesterone receptor (PR), and tumor protein 53 (P53) status were analyzed.
|
23133541 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptors are composed of the single-chain variable fragment (scFv) of a tumor-recognizing antibody cloned in frame with human T-cell signaling domains (e.g., CD3zeta, CD28, OX40, 4-1BB), thus combining the specificity of antibodies with the effector functions of cytotoxic T cells.
|
20387166 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Having transferred receptors encompassing the CD28, 4-1BB, and/or CD3zeta cytoplasmic domains in primary human CD8(+) T cells, we find that the P28BBz receptor, which includes all three signaling domains, is superior to receptors that only include one or two of these domains in promoting cytokine release, in vivo T-cell survival and tumor elimination following intravenous T-cell administration to tumor-bearing severe combined immunodeficient (SCID)/beige mice.
|
19773745 |
2010 |